Sanofi Expands Vaccine Portfolio and Gains China Approval for Rare Disease Drugs

Sanofi ( (SNY) ) just unveiled an update.

In December 2025, Sanofi announced the completion of its acquisition of Vicebio Ltd, which enhances its capabilities in vaccine design and development. This acquisition introduces an early-stage combination vaccine candidate for respiratory syncytial virus (RSV) and human metapneumovirus (HMPV), expanding Sanofi’s respiratory vaccine portfolio with a non-mRNA option. Additionally, Sanofi received approval in China for its drugs Qfitlia and Cablivi, which are intended to expand care for rare diseases, marking a significant step in broadening its market reach and strengthening its position in the global pharmaceutical industry.

The most recent analyst rating on (SNY) stock is a Buy with a $56.00 price target. To see the full list of analyst forecasts on Sanofi stock, see the SNY Stock Forecast page.

Spark’s Take on SNY Stock

According to Spark, TipRanks’ AI Analyst, SNY is a Outperform.

Sanofi’s overall stock score reflects its strong earnings performance and attractive valuation, which are the most significant factors. The company’s financial stability and positive earnings call guidance further support the score, despite some technical analysis indicators suggesting a neutral trend.

To see Spark’s full report on SNY stock, click here.

More about Sanofi

Sanofi is a research and development-driven, AI-powered biopharmaceutical company focused on improving people’s lives through innovative medicines and vaccines. The company leverages its deep understanding of the immune system to address urgent healthcare, environmental, and societal challenges, aiming to deliver growth and positive impact globally. Sanofi is publicly traded on EURONEXT and NASDAQ.

Average Trading Volume: 2,958,575

Technical Sentiment Signal: Buy

Current Market Cap: $118.3B

Find detailed analytics on SNY stock on TipRanks’ Stock Analysis page.